Felix Frueh is a respected thought leader in personalized medicine with twenty-five years of R&D, management, and policy experience. He founded Opus Three in 2012 after spending several years at the FDA and in the payer environment working closely with the pharmaceutical and diagnostic industry.
Frueh is also an entrepreneur, having founded or supported the founding of several startup companies. He is a mentor at the Institute for the Global Entrepreneur at the University of California San Diego (UCSD) and worked as entrepreneur-in-residence at Third Rock Ventures in Boston and San Francisco.
He was Chief Scientific Officer at Human Longevity, Inc. in San Diego, CA, and was President of the Medco Research Institute, in Bethesda, MD, leading the PBM’s clinical research initiatives in health economics and outcomes research after having formed Medco’s personalized medicine R&D organization. Prior, he was the first Associate Director for Genomics at FDA/CDER, where he oversaw the development and implementation of policies around biomarker qualification and companion diagnostics.
Frueh is a Board member at Enterome Biosciences, Ariana Pharma, Intellos Health, and CredibleMeds, and also served on the Boards of TcLand Expression and the Personalized Medicine Coalition. He serves (or served) on several scientific advisory boards to pharma companies.
He is a Fellow of the American College of Clinical Pharmacology and held faculty positions at Georgetown University in Washington, DC and at the University of North Carolina. Dr. Frueh received his education at Stanford University and the University of Basel in Switzerland, where he graduated magna cum laude in biochemistry.